Overview
Broadly speaking, Mirador Analytics assists biopharma organizations with drug development and launch planning strategy.
More specifically, through our proprietary analytical tools and services, we assist organizations with Asset Evaluation, Portfolio Prioritization, Life Cycle Management, Business Development Transactional Services and Individual Identification. In doing so, we support biopharma organizations of all sizes in taking their drugs to market, strategic partnerships and/or securing investments.
More specifically, through our proprietary analytical tools and services, we assist organizations with Asset Evaluation, Portfolio Prioritization, Life Cycle Management, Business Development Transactional Services and Individual Identification. In doing so, we support biopharma organizations of all sizes in taking their drugs to market, strategic partnerships and/or securing investments.
Our Areas of Expertise
Global Commercial Strategy Development
Our offering is focused towards North America, Europe and Asia, but also includes further regions when appropriate.
Global Commercial Strategy includes but is not limited to: Disease Area Strategy, Competitive Landscape Assessment, Target Product Profile/Claim Development and Validation, Value Proposition Development and Validation, Pricing Strategy, Stakeholder Insights (Ad Board, Qualitative and Quantitative), and Strategic Project Support.
Global Commercial Strategy includes but is not limited to: Disease Area Strategy, Competitive Landscape Assessment, Target Product Profile/Claim Development and Validation, Value Proposition Development and Validation, Pricing Strategy, Stakeholder Insights (Ad Board, Qualitative and Quantitative), and Strategic Project Support.
US, EU & Global Forecasting Asset Valuation
Mirador Analytics and our team have a strong background in forecasting and asset valuation. We have an online tool providing clients with remote access to a US and EU forecasting platform. Additionally, we offer custom forecasts and bespoke model builds.
The Asset Evaluation Tool provides clients with a platform to produce forecasts and profit and loss statements while in the commercial stages of drug development.
Our forecasts are used across all stages of drug development but are typically utilised during phase 1 and phase 2. They are utilised by companies that are looking to value their assets, validate and develop their strategy, and also predict their potential future revenues and costs.
The Asset Evaluation Tool provides clients with a platform to produce forecasts and profit and loss statements while in the commercial stages of drug development.
Our forecasts are used across all stages of drug development but are typically utilised during phase 1 and phase 2. They are utilised by companies that are looking to value their assets, validate and develop their strategy, and also predict their potential future revenues and costs.
Compound and Portfolio Assessment and Prioritisation
Supports strategic decision-making, providing multiple options for opportunity evaluation. This includes prioritising one compound across a breadth of indication opportunities, and assessing multiple compounds across multiple indications and disease areas. Our Portfolio Prioritisation services are offered in development stages and in commercialised compounds, across multiple geographies. Supported by our proprietary PIC tool.
US, EU & Global Payer Reimbursement, Risk Assessment & Mitigation
Mirador supports payer strategy development through anticipation and identification of potential risks. We work closely with clients to develop best courses of action to mitigate against these risks. This can include strengthening claims, and/or organising payer and customer ad boards.
Business Development Services
Mirador supports clients with their BD activities. More specifically, we support: Scouting, diligence and transactions; Strategic reviews and valuations; Sourcing partners and deal negotiations; and Validation.
These services can be supported by our Asset Evaluation Tool.
These services can be supported by our Asset Evaluation Tool.
KOL Mapping & Identification Platforms, Trial/Study Solutions
From early stage; supporting the discovery of potential investigators for clinical trials or key opinion leaders to discuss patient pathways, to later stage; identifying prescribers and helping build sales territories. Linked to our Individual Identification Database (IID)
Commercial Roadmap and Launch Planning
Mirador supports investment decisions and launch planning preparations. We assist clients in optimising their development pathway, providing advice on core activities to complete to support successful launches. See Global Strategy Development above for details on services included in building your strategy.
Life-Cycle Management
Developing a robust Lifecycle Management Strategy will enable you to identify potential further opportunities to improve the lives of patients and to continue to deliver additional value to your company throughout the life cycle of the asset. Mirador's rigorous cross-functional evaluation of potential opportunity areas will enable you to make strategic decisions on target indications in which to invest further. Mirador Analytics can assist you at each step in this process, from beginning to end. This service can be supported by our proprietary PIC tool.
Our Analytical Models and Tools
Mirador Analytics has a variety of tools and frameworks that link with our services to provide outputs with; structure, rigour, and visualisation to help our clients build a clearer picture of their environment,
Please follow the links below to find out more about each of Mirador's Tools, if you want further information you can also contact us and we'll get in touch with you.
Please follow the links below to find out more about each of Mirador's Tools, if you want further information you can also contact us and we'll get in touch with you.